Pharmedic Pharmaceutical Medicinal Joint Stock Company (HSTC:PMC) Return-on-Tangible-Equity: 0.00% (As of . 20)


What is Pharmedic Pharmaceutical Medicinal Joint Stock Company Return-on-Tangible-Equity?

Pharmedic Pharmaceutical Medicinal Joint Stock Company HSTC:PMC -0.77% Return-on-Tangible-Equity is 0.00% as of . 20.

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Pharmedic Pharmaceutical Medicinal Joint Stock Company's annualized net income for the quarter that ended in . 20 was ₫ Mil. Pharmedic Pharmaceutical Medicinal Joint Stock Company's average shareholder tangible equity for the quarter that ended in . 20 was ₫ Mil. Therefore, Pharmedic Pharmaceutical Medicinal Joint Stock Company's annualized Return-on-Tangible-Equity for the quarter that ended in . 20 was %.

The historical rank and industry rank for Pharmedic Pharmaceutical Medicinal Joint Stock Company's Return-on-Tangible-Equity or its related term are showing as below:

HSTC:PMC's Return-on-Tangible-Equity is not ranked *
in the Drug Manufacturers industry.
Industry Median: 7.9
* Ranked among companies with meaningful Return-on-Tangible-Equity only.

Pharmedic Pharmaceutical Medicinal Joint Stock Company  (HSTC:PMC) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.

Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.

Pharmedic Pharmaceutical Medicinal Joint Stock Company Return-on-Tangible-Equity Related Terms

Pharmedic Pharmaceutical Medicinal Joint Stock Company Return-on-Tangible-Equity Historical Data

* Premium members only.

The historical data trend for Pharmedic Pharmaceutical Medicinal Joint Stock Company's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pharmedic Pharmaceutical Medicinal Joint Stock Company Return-on-Tangible-Equity Chart

Pharmedic Pharmaceutical Medicinal Joint Stock Company Annual Data
Trend
Return-on-Tangible-Equity

Pharmedic Pharmaceutical Medicinal Joint Stock Company Quarterly Data
Return-on-Tangible-Equity

HSTC:PMC vs IMNPQ: Return-on-Tangible-Equity Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Pharmedic Pharmaceutical Medicinal Joint Stock Company's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pharmedic Pharmaceutical Medicinal Joint Stock Company Return-on-Tangible-Equity vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Pharmedic Pharmaceutical Medicinal Joint Stock Company's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where Pharmedic Pharmaceutical Medicinal Joint Stock Company's Return-on-Tangible-Equity falls into.


Pharmedic Pharmaceutical Medicinal Joint Stock Company Return-on-Tangible-Equity Calculation

Pharmedic Pharmaceutical Medicinal Joint Stock Company's annualized Return-on-Tangible-Equity for the fiscal year that ended in . 20 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: . 20 )  (A: . 20 )(A: . 20 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: . 20 )  (A: . 20 )(A: . 20 )
=/( (+ )/ )
=/
= %

Pharmedic Pharmaceutical Medicinal Joint Stock Company's annualized Return-on-Tangible-Equity for the quarter that ended in . 20 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: . 20 )  (Q: . 20 )(Q: . 20 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: . 20 )  (Q: . 20 )(Q: . 20 )
=/( (+)/ )
=/
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (. 20) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.

What does a Return-on-Tangible-Equity of 0.00% mean?
Pharmedic Pharmaceutical Medicinal Joint Stock Company (HSTC:PMC) has a Return-on-Tangible-Equity of 0.00% as of . 20. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Pharmedic Pharmaceutical Medicinal Joint Stock Company and its competitors.
Is Pharmedic Pharmaceutical Medicinal Joint Stock Company's Return-on-Tangible-Equity too high?
Pharmedic Pharmaceutical Medicinal Joint Stock Company's current Return-on-Tangible-Equity is 0.00%.
How does Pharmedic Pharmaceutical Medicinal Joint Stock Company's Return-on-Tangible-Equity compare to IMNPQ?
Pharmedic Pharmaceutical Medicinal Joint Stock Company's Return-on-Tangible-Equity of 0.00% can be compared against companies in the Drug Manufacturers industry. The industry median Return-on-Tangible-Equity is 7.90. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Drug Manufacturers company?
The median Return-on-Tangible-Equity among Drug Manufacturers companies is 7.90, based on 897 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Pharmedic Pharmaceutical Medicinal Joint Stock Company and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Equity is 7.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pharmedic Pharmaceutical Medicinal Joint Stock Company's current Return-on-Tangible-Equity is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharmedic Pharmaceutical Medicinal Joint Stock Company stock overvalued right now?
Pharmedic Pharmaceutical Medicinal Joint Stock Company (HSTC:PMC) has a current Return-on-Tangible-Equity of 0.00%. The current Return-on-Tangible-Equity is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Pharmedic Pharmaceutical Medicinal Joint Stock Company (HSTC:PMC), the current Return-on-Tangible-Equity is 0.00% as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Pharmedic Pharmaceutical Medicinal Joint Stock Company Business Description

Address 367 Nguyen Trai, Nguyen Cu Trinh Ward, District 1, TP. HCM, Ho Chi Minh, VNM
Pharmedic Pharmaceutical Medicinal Joint Stock Company is involved in the production and sales of pharmaceutical products, cosmetics, medical supplies, and other products in the health sector. The company's products include Farzincol Bottle, Farzincol Syrup, Sibemag, Vitamin C 50, Vitamin PP 500, Vitamin PP 50, Nacofar, Cooldrop, Inhaler, Povidine 10% 90ml, Povidine 4% 500, Povidine 10% 8ml, and Povidine 4% 800.